Factor VIII - Shire

Drug Profile

Factor VIII - Shire

Alternative Names: Factor VIII autologous cell therapy - Shire Pharmaceuticals; Factor VIII autologous cell therapy - Transkaryotic Therapies; Factor VIII cell therapy - Shire Pharmaceuticals; Factor VIII cell therapy - Transkaryotic Therapies; Factor VIII replacement therapy - Shire; FVIII therapy - Shire

Latest Information Update: 22 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Developer Rani Therapeutics; Shire
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Factor VIII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Haemophilia A

Most Recent Events

  • 06 Dec 2017 Early research in Haemophilia A in Ireland (PO)
  • 05 Dec 2017 Shire and Rani Therapeutics agree to evaluate the use of the Rani Pill™ technology for oral delivery of factor VIII therapy for haemophilia A
  • 02 May 2007 No development reported - Phase-I for Haemophilia A in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top